Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323476 | 0.91 | RIPK1 (0.54) | RIPK1IGF1RCDK1CDK2KDR | |
| SCHEMBL4722549 | 0.90 | FLT3 (0.52) | RIPK1GRIK1KDREPHB4TEK | |
| SCHEMBL4723867 | 0.85 | TEK (0.46) | RIPK1KDREPHB4TEKBRAF | |
| SCHEMBL16456547 | 0.84 | RIPK1 (0.54) | RIPK1IGF1RCDK1CDK2KDR | |
| SCHEMBL1323850 | 0.82 | KDR (0.53) | RIPK1CDK1CDK2KDRTEK | |
| SCHEMBL1321944 | 0.82 | EPHX2 (0.56) | RIPK1KDRBRAF | |
| SCHEMBL4764222 | 0.82 | PDGFRB (0.39) | RIPK1GRIK1KDRTEKBRAF | |
| SCHEMBL4912208 | 0.81 | NPC1 (0.39) | RIPK1GRIK1KDRTEKMEN1 | |
| SCHEMBL4766324 | 0.81 | KDR (0.40) | RIPK1GRIK1KDRTEKBRAF | |
| SCHEMBL1322572 | 0.81 | FLT3 (0.52) | RIPK1KDRTEKKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912988-B1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2014-04-16 | — | — | EP | claimed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | claimed |
| EP-1912988-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-04-23 | — | — | EP | claimed |
| WO-2007017577-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | RIPK1 1043/4885GRIK1 1704/4885IGF1R 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.